Skip to content
The Policy VaultThe Policy Vault

Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) — United Healthcare

Chronic hepatitis C genotype 1, 2, 3, 4, 5, or 6 infection in treatment-experienced patients with an NS5A inhibitor-based regimen without cirrhosis or with compensated cirrhosis

Initial criteria

  • Diagnosis of chronic hepatitis C genotype 1, 2, 3, 4, 5 or 6 infection
  • AND Patient has prior treatment experience with an HCV NS5A inhibitor [e.g., Daklinza (daclatasvir), Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir), Viekira (dasabuvir/ombitasvir/paritaprevir/ritonavir), Zepatier (elbasvir/grazoprevir)]
  • AND One of the following: (a) Patient is without cirrhosis OR (b) Patient has compensated cirrhosis (Child-Pugh A)
  • AND Patient is not receiving Vosevi in combination with another HCV direct acting antiviral agent [e.g., Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir), Mavyret (glecaprevir/pibrentasvir), Sovaldi (sofosbuvir), Zepatier (elbasvir/grazoprevir)]

Approval duration

12 weeks